Q2 EPS Estimates for Legend Biotech Boosted by HC Wainwright

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) – Equities researchers at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for Legend Biotech in a research report issued on Wednesday, July 15th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of $0.22 for the quarter, up from their prior forecast of $0.18. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($0.01) per share. HC Wainwright also issued estimates for Legend Biotech’s Q3 2026 earnings at $0.16 EPS.

LEGN has been the topic of several other reports. JPMorgan Chase & Co. assumed coverage on shares of Legend Biotech in a report on Monday. They issued a “neutral” rating and a $35.00 price objective on the stock. Truist Financial downgraded shares of Legend Biotech from a “strong-buy” rating to a “hold” rating in a report on Friday, March 20th. Weiss Ratings lowered shares of Legend Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 10th. Morgan Stanley lowered their price target on shares of Legend Biotech from $49.00 to $48.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Finally, TD Cowen raised their price objective on shares of Legend Biotech to $29.00 and gave the stock a “hold” rating in a research report on Wednesday, May 13th. Nine investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $57.00.

Legend Biotech Price Performance

Shares of LEGN stock opened at $22.71 on Thursday. The company has a fifty day moving average price of $29.44 and a two-hundred day moving average price of $23.33. Legend Biotech has a one year low of $16.24 and a one year high of $45.30. The stock has a market cap of $4.22 billion, a P/E ratio of -33.40 and a beta of 0.34.

Legend Biotech (NASDAQ:LEGN) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.01). The company had revenue of $305.10 million for the quarter, compared to analyst estimates of $306.51 million. Legend Biotech had a negative return on equity of 24.92% and a negative net margin of 21.98%.The firm’s revenue for the quarter was up 56.5% compared to the same quarter last year. During the same period last year, the firm earned ($0.07) EPS.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC lifted its stake in Legend Biotech by 6,774.9% during the fourth quarter. SG Americas Securities LLC now owns 371,728 shares of the company’s stock worth $8,081,000 after purchasing an additional 366,321 shares during the last quarter. Hudson Bay Capital Management LP raised its holdings in shares of Legend Biotech by 42.4% during the 3rd quarter. Hudson Bay Capital Management LP now owns 220,000 shares of the company’s stock worth $7,174,000 after buying an additional 65,500 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Legend Biotech during the 1st quarter worth $4,039,000. Casdin Capital LLC bought a new stake in shares of Legend Biotech during the 4th quarter worth $4,674,000. Finally, Eagle Health Investments LP acquired a new stake in Legend Biotech in the fourth quarter valued at about $8,884,000. Institutional investors own 70.89% of the company’s stock.

Insider Activity

In related news, CEO Ying Huang sold 5,566 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $14.78, for a total value of $82,265.48. Following the completion of the sale, the chief executive officer directly owned 241,872 shares in the company, valued at approximately $3,574,868.16. The trade was a 2.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.02% of the company’s stock.

Legend Biotech Company Profile

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.